152 related articles for article (PubMed ID: 19888241)
1. Questions regarding use of infliximab and risk of certain viral infections.
El-Matary W
Am J Gastroenterol; 2009 Nov; 104(11):2852; author reply 2852-3. PubMed ID: 19888241
[No Abstract] [Full Text] [Related]
2. Viral infections in patients with inflammatory bowel disease on immunosuppressants.
Ali T; Yun L; Shapiro D; Madhoun MF; Bronze M
Am J Med Sci; 2012 Mar; 343(3):227-32. PubMed ID: 22357111
[TBL] [Abstract][Full Text] [Related]
3. Viral infections associated with the clinical use of monoclonal antibodies.
Gentile G; Foà R
Clin Microbiol Infect; 2011 Dec; 17(12):1769-75. PubMed ID: 22023708
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B and C virus prevalence and related factors in patients with inflammatory bowel diseases.
Yakut M; Kabaçam G; Üstün Y; Cetinkaya H; Soykan I
Clin Res Hepatol Gastroenterol; 2011 Dec; 35(12):857. PubMed ID: 21963993
[No Abstract] [Full Text] [Related]
5. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions.
de Vries HS; van Oijen MG; van Hoven-van Loo KE; de Jong DJ
J Clin Gastroenterol; 2009 Apr; 43(4):387-8. PubMed ID: 18987555
[No Abstract] [Full Text] [Related]
6. Viral infection and reactivation in autoimmune disease.
Chakravarty EF
Arthritis Rheum; 2008 Oct; 58(10):2949-57. PubMed ID: 18821704
[No Abstract] [Full Text] [Related]
7. [Inflammatory bowel disease: should all patients be premedicated when infliximab is administered to reduce infusion reactions and/or immunogenicity?].
Ginard D; Mariño Z
Gastroenterol Hepatol; 2008 Oct; 31(8):542-3. PubMed ID: 18928758
[No Abstract] [Full Text] [Related]
8. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis.
Becker M; Rosé CD; McIlvain-Simpson G
J Rheumatol; 2004 Dec; 31(12):2529-30. PubMed ID: 15570667
[No Abstract] [Full Text] [Related]
9. Safety of infliximab in inflammatory bowel disease needs to be debated.
de Vries HS; Van Oijen MG; de Jong DJ
Clin Gastroenterol Hepatol; 2009 May; 7(5):603-4. PubMed ID: 19166980
[No Abstract] [Full Text] [Related]
10. Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604.
Caspersen S; Mortensen C; Riis L; Jess T; Bendtsen F
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1257. PubMed ID: 19778634
[No Abstract] [Full Text] [Related]
11. Monoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz A; Mayer L
Mt Sinai J Med; 2005 Jul; 72(4):250-6. PubMed ID: 16021319
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody use in inflammatory bowel disease.
Hayes CE; Cerezo CS
Med Health R I; 2011 Nov; 94(11):337-40. PubMed ID: 22204097
[No Abstract] [Full Text] [Related]
13. Trends in prevalence of viral infections in Australian musculoskeletal tissue donors and projections of incidence and residual risk, 1993-2004.
Yao F; Seed C; Kiely P; Parker S; Qian Y; Farrugia A; Morgan D; Wood D; Zheng MH
Transplantation; 2008 Sep; 86(5):746-8. PubMed ID: 18791459
[No Abstract] [Full Text] [Related]
14. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
Rosh JR; Oliva-Hemker M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
[No Abstract] [Full Text] [Related]
15. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
Bujanover Y; Weiss B
Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
[No Abstract] [Full Text] [Related]
16. Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis.
Nobile S; Catassi C; Felici L
J Clin Rheumatol; 2009 Mar; 15(2):101. PubMed ID: 19265360
[No Abstract] [Full Text] [Related]
17. [Viral hepatitis and alcohol: a synergistic relationship].
Kershenobich D
Rev Gastroenterol Mex; 1995; 60(4 Suppl 2):S56. PubMed ID: 8948781
[No Abstract] [Full Text] [Related]
18. Viral infections in immunosuppressed patients.
Hirschman SZ
N Y State J Med; 1984 May; 84(5):241-4. PubMed ID: 6330629
[No Abstract] [Full Text] [Related]
19. [The spread of hepatitis B and C markers and the etiological structure of the morbidity with acute viral hepatitis of the population in the Kuznetsk Basin and northwestern Kazakhstan].
Kruglov IV; Iashina TL; Tsvetova GV; Seliutina IA; Klimkin AIu; Aksenova NF; Sobina GV; Gerasimenko NA; Bakulin VS; Ivanov SV
Zh Mikrobiol Epidemiol Immunobiol; 1995; (6):36-7. PubMed ID: 8553742
[No Abstract] [Full Text] [Related]
20. [IL-17/IL-23: a new therapeutic target in inflammatory bowel diseases].
Malamut G
Gastroenterol Clin Biol; 2008 Mar; 32(3):354-6. PubMed ID: 18374530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
